Akero Therapeutics Inc (AKRO)

$25.14 +1.13 (4.71%)
Market Cap 1.68B
Revenue (ttm) 0.00
Net Income (ttm) -151.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 1,229,100
Avg Vol 709,994
Day's Range N/A - N/A
Shares Out 69.80M
Stochastic %K 50%
Beta -0.19
Analysts Strong Sell
Price Target $48.27

Latest News on AKRO

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Jan 14, 2025, 10:00 AM EST - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Jan 13, 2025, 10:00 AM EST - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Jan 12, 2025, 10:00 AM EST - 5 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

Jan 10, 2025, 10:00 AM EST - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

Jan 9, 2025, 10:00 AM EST - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

Jan 8, 2025, 10:00 AM EST - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 7, 2025, 10:00 AM EST - 10 days ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

Jan 6, 2025, 10:00 AM EST - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

Jan 3, 2025, 10:00 AM EST - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jan 2, 2025, 10:00 AM EST - 15 days ago

Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

Jan 2, 2025, 10:00 AM EST - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

Dec 31, 2024, 10:00 AM EST - 17 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

Dec 30, 2024, 2:45 PM EST - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Dec 22, 2024, 10:00 AM EST - 26 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Nov 15, 2024, 11:00 AM EST - 2 months ago

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 2 months ago

Akero Therapeutics to Present at the Jefferies London Healthcare Conference

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 8, 2024, 7:00 AM EST - 2 months ago

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

Oct 21, 2024, 7:00 AM EDT - 3 months ago

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Sep 30, 2024, 9:37 PM EDT - 3 months ago

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Sep 30, 2024, 7:00 AM EDT - 3 months ago

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

Akero Therapeutics: Good Candidate For The MASH Basket

Sep 20, 2024, 3:37 PM EDT - 4 months ago

Akero Therapeutics: Good Candidate For The MASH Basket

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 28, 2024, 4:05 PM EDT - 5 months ago

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 9, 2024, 7:00 AM EDT - 5 months ago

Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

Jun 28, 2024, 10:40 AM EDT - 7 months ago

Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Jun 21, 2024, 10:40 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Jun 16, 2024, 11:18 AM EDT - 7 months ago

AKRO ANNOUNCEMENT: If You Have Suffered Losses in Akero Therapeutics, Inc. (NASDAQ: AKRO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Jun 11, 2024, 3:46 PM EDT - 7 months ago

AKRO INVESTOR NOTICE: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Jun 11, 2024, 7:00 AM EDT - 7 months ago

Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

Jun 8, 2024, 8:15 AM EDT - 7 months ago

Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Jun 6, 2024, 10:15 AM EDT - 8 months ago

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Jun 5, 2024, 12:00 PM EDT - 8 months ago

IMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

Jun 5, 2024, 11:15 AM EDT - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Jun 5, 2024, 10:20 AM EDT - 8 months ago

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc. with Losses to Contact the Firm

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 8 months ago

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 7:00 AM EDT - 9 months ago

Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

May 8, 2024, 7:00 AM EDT - 9 months ago

Akero Therapeutics to Present at the BofA Securities 2024 Health Care Conference

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors

May 3, 2024, 10:00 AM EDT - 9 months ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors

May 2, 2024, 2:47 PM EDT - 9 months ago

The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Apr 30, 2024, 8:00 AM EDT - 9 months ago

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.

Apr 2, 2024, 6:05 PM EDT - 10 months ago

Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc.